Multiscale Modeling of Influenza A Virus Infection Supports the Development of Direct-Acting Antivirals

PLoS Computational Biology

Volumn 9, Issue 11, 2013, Pages

  Heldt, Frank S ^a   Frensing, Timo ^a   Pflugmacher, Antje ^a   Gröpler, Robin ^b   Peschel, Britta ^a   Reichl, Udo ^a,b  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSYNTHESIS; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; DISEASE CONTROL; DISEASES; ENZYME ACTIVITY; LIFE CYCLE;

ANTIVIRALS; DRUG TARGETS; DRUG-RESISTANT STRAINS; EXTRACELLULAR LEVELS; INFECTED CELLS; INFLUENZA A VIRUS; INTRACELLULAR LEVELS; MULTISCALE MODELING; VIRAL REPLICATION; VIRUS INFECTION;

VIRUSES;

ANTIVIRUS AGENT; MESSENGER RNA; VIRUS RNA;

APOPTOSIS; ARTICLE; CELL POPULATION; ENDOCYTOSIS; IMMUNE RESPONSE; INFLUENZA A; INFLUENZA VIRUS A; NONHUMAN; PROTEIN SYNTHESIS; RNA SYNTHESIS; VIRION; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS PARTICLE; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TITRATION;

INFLUENZA A VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CELL DEATH; COMPUTATIONAL BIOLOGY; DOGS; DRUG DISCOVERY; EXTRACELLULAR SPACE; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INTRACELLULAR SPACE; MADIN DARBY CANINE KIDNEY CELLS; MODELS, BIOLOGICAL; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84888213986     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003372     Document Type: Article

References (60)

1. WHO (2009) Influenza fact sheet No 211.
2. Taubenberger JK, Morens DM, (2006) 1918 influenza: the mother of all pandemics. Emerging Infectious Diseases 12: 15-22.
3. Center for Disease Control and Prevention (2012) Influenza Antiviral Medications: A Summary for Clinicians.
4. Sheu TG, Fry AM, Garten RJ, Deyde VM, Shwe T, et al. (2011) Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A(H1N1) Viruses: 2008-2010. Journal of Infectious Diseases 203: 13-17.
5. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrobial Agents and Chemotherapy 52: 3284-3292.
6. Muller KH, Kakkola L, Nagaraj AS, Cheltsov AV, Anastasina M, et al. (2012) Emerging cellular targets for influenza antiviral agents. Trends in Pharmacological Sciences 33: 89-99.
7. Planz O, (2013) Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Research 98: 457-468.
8. Das K, (2012) Antivirals Targeting Influenza A Virus. Journal of Medicinal Chemistry 55: 6263-6277.
9. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS, (2006) Kinetics of influenza A virus infection in humans. Journal of Virology 80: 7590-7599.
10. Handel A, Longini IM, Antia R, (2007) Neuraminidase inhibitor resistance in influenza: Assessing the danger of its generation and spread. Plos Computational Biology 3: 2456-2464.
11. Beauchemin CAA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, et al. (2008) Modeling amantadine treatment of influenza A virus in vitro. Journal of Theoretical Biology 254: 439-451.
12. Lee HY, Topham DJ, Park SY, Hollenbaugh J, Treanor J, et al. (2009) Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection. Journal of Virology 83: 7151-7165.
13. Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CAA, (2011) Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study. Journal of Theoretical Biology 269: 234-244.
14. Smith AM, Perelson AS, (2011) Influenza A virus infection kinetics: quantitative data and models. Wiley Interdisciplinary Reviews-Systems Biology and Medicine 3: 429-445.
15. Beauchemin CAA, Handel A, (2011) A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. Bmc Public Health 11: S7.
16. Lloyd AL, (2001) The dependence of viral parameter estimates on the assumed viral life cycle: limitations of studies of viral load data. Proceedings of the Royal Society B-Biological Sciences 268: 847-854.
17. Kim H, Yin J, (2004) Quantitative analysis of a parasitic antiviral strategy. Antimicrobial Agents and Chemotherapy 48: 1017-1020.
18. Reddy B, Yin J, (1999) Quantitative intracellular kinetics of HIV type 1. Aids Research and Human Retroviruses 15: 273-283.
19. Endy D, Yin J, (2000) Toward antiviral strategies that resist viral escape. Antimicrobial Agents and Chemotherapy 44: 1097-1099.
20. Guedj J, Dahari H, Rong LB, Sansone ND, Nettles RE, et al. (2013) Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proceedings of the National Academy of Sciences of the United States of America 110: 3991-3996.
21. Guedj J, Neumann AU, (2010) Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. Journal of Theoretical Biology 267: 330-340.
22. Haseltine EL, Rawlings JB, Yin J, (2005) Dynamics of viral infections: incorporating both the intracellular and extracellular levels. Computers & Chemical Engineering 29: 675-686.
23. Haseltine EL, Yin J, Rawlings JB, (2008) Implications of Decoupling the Intracellular and Extracellular Levels in Multi-Level Models of Virus Growth. Biotechnology and Bioengineering 101: 811-820.
24. Holder BP, Beauchemin CAA, (2011) Exploring the effect of biological delays in kinetic models of influenza within a host or cell culture. Bmc Public Health 11: S10.
25. Heldt FS, Frensing T, Reichl U, (2012) Modeling the Intracellular Dynamics of Influenza Virus Replication To Understand the Control of Viral RNA Synthesis. Journal of Virology 86: 7806-7817.
26. Hay AJ, Lomniczi B, Bellamy AR, Skehel JJ, (1977) Transcription of Influenza-Virus Genome. Virology 83: 337-355.
27. Skehel JJ, Hay AJ, Armstrong JA, (1978) Mechanism of Inhibition of Influenza-Virus Replication by Amantadine Hydrochloride. Journal of General Virology 38: 97-110.
28. Hankins RW, Nagata K, Kato A, Ishihama A, (1990) Mechanism of influenza virus transcription inhibition by matrix (M1) protein. Res Virol 141: 305-314.
29. Watanabe K, Handa H, Mizumoto K, Nagata K, (1996) Mechanism for inhibition of influenza virus RNA polymerase activity by matrix protein. J Virol 70: 241-247.
30. Zvonarjev AY, Ghendon YZ, (1980) Influence of membrane (M) protein on influenza A virus virion transcriptase activity in vitro and its susceptibility to rimantadine. J Virol 33: 583-586.
31. Lamb RA, Krug RM (2001) Orthomyxoviridae: the viruses and their replication. Fields virology, 4th ed: p.1487-1531. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Philadelphia: Lippincott Williams & Wilkins.
32. Murillo LN, Murillo MS, Perelson AS, (2013) Towards multiscale modeling of influenza infection. J Theor Biol 332: 267-90.
33. Schulze-Horsel J, Schulze M, Agalaridis G, Genzel Y, Reichl U, (2009) Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production-Flow cytometry and mathematical modeling. Vaccine 27: 2712-2722.
34. Grossman Z, Polis M, Feinberg MB, Grossman Z, Levi I, et al. (1999) Ongoing HIV dissemination during HAART. Nature Medicine 5: 1099-1104.
35. Isken B, Genzel Y, Reichl U, (2012) Productivity, apoptosis, and infection dynamics of influenza A/PR/8 strains and A/PR/8-based reassortants. Vaccine 30: 5253-5261.
36. Resa-Infante P, Jorba N, Coloma R, Ortin J, (2011) The influenza virus RNA synthesis machine: advances in its structure and function. RNA Biol 8: 207-215.
37. Manz B, Brunotte L, Reuther P, Schwemmle M, (2012) Adaptive mutations in NEP compensate for defective H5N1 RNA replication in cultured human cells. Nat Commun 3: 802.
38. Perez JT, Zlatev I, Aggarwal S, Subramanian S, Sachidanandam R, et al. (2012) A small-RNA enhancer of viral polymerase activity. J Virol 86: 13475-13485.
39. Frensing T, Heldt FS, Pflugmacher A, Behrendt I, Jordan I, et al. (2013) Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles. PLoS One 8: e72288.
40. Dobrovolny HM, Reddy MB, Kamal MA, Rayner CR, Beauchemin CAA, (2013) Assessing Mathematical Models of Influenza Infections Using Features of the Immune Response. Plos One 8: e57088 doi:10.1371/journal.pone.0057088.
41. Handel A, Longini IM, Antia R, (2010) Towards a quantitative understanding of the within-host dynamics of influenza A infections. Journal of the Royal Society Interface 7: 35-47.
42. Pawelek KA, Huynh GT, Quinlivan M, Cullinane A, Rong LB, et al. (2012) Modeling Within-Host Dynamics of Influenza Virus Infection Including Immune Responses. Plos Computational Biology 8: e1002588 doi:10.1371/journal.pcbi.1002588.
43. Hastings JC, Selnick H, Wolanski B, Tomassini JE, (1996) Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrobial Agents and Chemotherapy 40: 1304-1307.
44. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, et al. (2005) Mechanism of action of T-705 against influenza virus. Antimicrobial Agents and Chemotherapy 49: 981-986.
45. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, et al. (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrobial Agents and Chemotherapy 46: 977-981.
46. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, et al. (2010) T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proceedings of the National Academy of Sciences of the United States of America 107: 882-887.
47. Wathen MW, Barro M, Bright RA, (2013) Antivirals in seasonal and pandemic influenza- future perspectives. Influenza and Other Respiratory Viruses 7: 76-80.
48. Ghanem A, Mayer D, Chase G, Tegge W, Frank R, et al. (2007) Peptide-mediated interference with influenza A virus polymerase. Journal of Virology 81: 7801-7804.
49. Muratore G, Goracci L, Mercorelli B, Foeglein A, Digard P, et al. (2012) Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proceedings of the National Academy of Sciences of the United States of America 109: 6247-6252.
50. Smith AM, Ribeiro RM, (2010) Modeling the Viral Dynamics of Influenza A Virus Infection. Critical Reviews in Immunology 30: 291-298.
51. Smith AM, Adler FR, McAuley JL, Gutenkunst RN, Ribeiro RM, et al. (2011) Effect of 1918 PB1-F2 Expression on Influenza A Virus Infection Kinetics. Plos Computational Biology 7: e1001081 doi:10.1371/journal.pcbi.1001081.
52. Huang IC, Li WH, Sui JH, Marasco W, Choe H, et al. (2008) Influenza A virus neuraminidase limits viral superinfection. Journal of Virology 82: 4834-4843.
53. Cohen SD, Hindmarsh AC, (1996) CVODE, a stiff/nonstiff ODE solver in C. Computers in Physics 10: 138-143.
54. Schmidt H, Jirstrand M, (2006) Systems Biology Toolbox for MATLAB: a computational platform for research in systems biology. Bioinformatics 22: 514-515.
55. Egea JA, Rodriguez-Fernandez M, Banga JR, Marti R, (2007) Scatter search for chemical and bio-process optimization. Journal of Global Optimization 37: 481-503.
56. Efron B, Tibshirani R, (1986) Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy. Statistical Science 1: 54-75.
57. Kalbfuss B, Knochlein A, Krober T, Reichl U, (2008) Monitoring influenza virus content in vaccine production: Precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 36: 145-161.
58. Burleson FG, Chambers TM, Wiedbrauk DL (1992) Hemagglutination Assay. In: Virology- A Laboratory Manual. San Diego: Academic Press. pp. 86-92.
59. Genzel Y, Reichl U (2007) Vaccine production- state of the art and future needs in upstream processing. In: Poertner R, editor. Animal cell biotechnology: methods and protocols: Humana Press Inc. pp. 457-473.
60. Kawakami E, Watanabe T, Fujii K, Goto H, Watanabe S, et al. (2011) Strand-specific real-time RT-PCR for distinguishing influenza vRNA, cRNA, and mRNA. Journal of Virological Methods 173: 1-6.